Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: Towards the HCM Heart Team
| Autor: | Hubert Seggewiss, Franco Cecchi, Paolo Ferrazzi, Giuseppe Limongelli, Martin S. Maron, Iacopo Olivotto, Magdi H. Yacoub, Juan Pablo Kaski, Claudio Rapezzi, Paolo Calabrò, Francesco Pelliccia, Felice Gragnano, Ottavio Alfieri |
|---|---|
| Přispěvatelé: | Pelliccia, F., Alfieri, O., Calabro, P., Cecchi, F., Ferrazzi, P., Gragnano, F., Kaski, J. P., Limongelli, G., Maron, M., Rapezzi, C., Seggewiss, H., Yacoub, M. H., Olivotto, I. |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Adult
Heart Defects Congenital medicine.medical_specialty Alcohol septal ablation 030204 cardiovascular system & hematology Ventricular Outflow Obstruction NO 03 medical and health sciences 0302 clinical medicine Ventricular hypertrophy Obstruction medicine Humans cardiovascular diseases 030212 general & internal medicine Myectomy Cardiac Surgical Procedures Intensive care medicine Gradient Hypertrophic cardiomyopathy Left ventricular outflow tract Genetic testing Heart Failure medicine.diagnostic_test Interventional cardiology business.industry Evidence-based medicine Cardiomyopathy Hypertrophic medicine.disease alcohol septal ablation cradient hypertrophic cardiomyopathy left ventricular outflow tract myectomy obstruction Cardiac surgery Heart failure cardiovascular system Cardiology and Cardiovascular Medicine business |
| Popis: | Patients with hypertrophic cardiomyopathy (HCM) exhibit a variable phenotype with ventricular hypertrophy as the cardinal manifestation and left ventricular (LV) outflow tract obstruction (LVOTO) as a key pathophysiologic determinant. Patients with severe LVOTO usually present with exertional dyspnea, exertional syncope, and heart failure symptoms, while successful relief of LVOTO by pharmacological or invasive interventions leads to a dramatic improvement in clinical status. Proper management of obstructive HCM remains challenging and poses numerous clinical dilemmas. Since the development of surgical myectomy over half a century ago, progress in the management of LVOTO in HCM has paralleled technological advances in genetic testing, cardiac imaging, arrhythmic prophylaxis, cardiac surgery and interventional cardiology. These changes have been incorporated in dedicated scientific guidelines on both sides of the Atlantic. However, either the 2011 American guidelines or the 2014 European guidelines remain largely based on expert consensus for lack of recommendations with level of evidence A regarding any of the treatment options commonly employed in HCM. Consequently, management of obstructive HCM patients remains largely subjective and dependent on clinical judgment, local expertise, and patient preference. Following the trend that has emerged for other cardiac diseases amenable to invasive interventions, adequate evaluation and management of obstruction in HCM today requires a multidisciplinary team capable of optimizing referral, choosing the best available options, minimizing complications and ensuring state-of-the-art results. The concept of an HCM Heart Team is coming of age. This review aims to provide an update of available pharmacologic and invasive options for the management of LVOTO in HCM, either in adulthood or in childhood, highlighting areas for multidisciplinary integration and future development. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|